Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Benchmark analyst Robert Wasserman reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $8 price target.
RBC Capital analyst Conor McNamara reiterates OmniAb (NASDAQ:OABI) with a Outperform and maintains $7 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $11 price target.
2024 Financial GuidanceOmniAb now expects total operating expenses in 2024 to be slightly less than total operating expenses in...
OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23....
Engineered chickens producing single domain antibodies (sdAbs) provided the scientific foundation for OmnidAb™, the Company'...
Technical synergies between xPloration, OmniFlic®, OmniClic® and OmniDeep®enable new bispecific antibody discovery workflows fo...
Benchmark analyst Robert Wasserman reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $8 price target.
OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.16) by 1...
